Accessibility Links

  1. Skip to Main Navigation
  2. Skip to Main Content



Remicade (infliximab)

BioOutsource offers a comprehensive range of services to support the biological evaluation of Remicade including characterisation, comparability, lot release and clinical assessments. Our off-the-shelf binding assays and bioassays include binding measurements for TNF-Alpha and the Fc-Receptors, C1q binding as well as the Remicade Complement Dependent Cytotoxicity assay (CDC assay) and Remicade Antibody Dependent Cellular Cytotoxicity assay (ADCC assay). A number of different potency assays are also available reflecting the diverse mechanisms of action of Remicade.

TNF-Alpha is a potent pro-inflammatory cytokine involved in a number of different diseases playing an integral role in autoimmune diseases. TNF-Alpha molecules are homotrimers and exist either as membrane TNF-alpha on cell surfaces (mTNF-alpha) or following cleavage of this membrane bound form by the TNF-alpha converting enzyme (TACE), exist as free molecules in solution (sTNF-Alpha). Two different classes of biological drug products that target TNF-Alpha have been approved; TNF-Alpha monoclonal antibodies (Infiximab and Adalimumab) and a soluble TNF-Alpha receptor (Etanercept). Each product class can bind to both the soluble and membrane-bound forms of TNF-Alpha.

Remicade (infliximab) is a chimeric monoclonal antibody and has been approved for the treatment of severe rheumatoid arthritis, ankolysing sponglylitis and moderate to severe Crohn’s disease amongst others. The antibody constitutes approximately 75% human and 25% murine protein, consisting of murine variable regions with a human Fc-Gamma-1 isotype.

The Fab-related binding function of Remicade (Infliximab) allows the antibody to bind to both soluble and membrane TNF-Alpha with high affinity preventing activation of the TNF receptors on TNF-Alpha sensitive cells. Following binding to mTNF-Alpha, Remicade mediates a range of additional biological responses including reverse signaling which  results in apoptosis and cytokine suppression, Complement Dependent Cytotoxicity (CDC) and Antibody Dependent Cellular Cytoxicity (ADCC). 

BioOutsource provides cutting edge methodologies using a range of novel cell lines allowing end to end support for Remicade biosimilar manufacturers. We have extensive experience, working with approximately 20 different anti-TNF-alpha therapeutic biosimilar products across the clinical phases: